215 related articles for article (PubMed ID: 36934059)
21. Emerging biological therapies for the treatment of myelodysplastic syndromes.
Zeidan AM; Stahl M; Komrokji R
Expert Opin Emerg Drugs; 2016 Sep; 21(3):283-300. PubMed ID: 27486848
[TBL] [Abstract][Full Text] [Related]
22. Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes.
Stankov K; Stankov S; Katanic J
Curr Pharm Des; 2017; 23(1):135-169. PubMed ID: 27697023
[TBL] [Abstract][Full Text] [Related]
23. CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice.
DeZern AE; Malcovati L; Ebert BL
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():400-410. PubMed ID: 31099654
[TBL] [Abstract][Full Text] [Related]
24. [Epigenetic dysregulation in myelodysplastic syndrome].
Sashida G; Iwama A
Rinsho Ketsueki; 2015 Feb; 56(2):111-8. PubMed ID: 25765789
[TBL] [Abstract][Full Text] [Related]
25. [Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes].
Nakajima H
Rinsho Ketsueki; 2023; 64(8):753-763. PubMed ID: 37673628
[TBL] [Abstract][Full Text] [Related]
26. The genetic and molecular pathogenesis of myelodysplastic syndromes.
Shallis RM; Ahmad R; Zeidan AM
Eur J Haematol; 2018 Sep; 101(3):260-271. PubMed ID: 29742289
[TBL] [Abstract][Full Text] [Related]
27. Therapy-related myelodysplastic syndromes, or are they?
Abou Zahr A; Kavi AM; Mukherjee S; Zeidan AM
Blood Rev; 2017 May; 31(3):119-128. PubMed ID: 27923516
[TBL] [Abstract][Full Text] [Related]
28. Current challenges and unmet medical needs in myelodysplastic syndromes.
Platzbecker U; Kubasch AS; Homer-Bouthiette C; Prebet T
Leukemia; 2021 Aug; 35(8):2182-2198. PubMed ID: 34045662
[TBL] [Abstract][Full Text] [Related]
29. Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.
Kerkhoff N; Bontkes HJ; Westers TM; de Gruijl TD; Kordasti S; van de Loosdrecht AA
Immunotherapy; 2013 Jun; 5(6):621-37. PubMed ID: 23725285
[TBL] [Abstract][Full Text] [Related]
30. Advances in myelodysplastic syndromes: promising novel agents and combination strategies.
Madanat YF; Xie Z; Zeidan AM
Expert Rev Hematol; 2023 Jan; 16(1):51-63. PubMed ID: 36620919
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
[TBL] [Abstract][Full Text] [Related]
32. Mutation-Driven Therapy in MDS.
Swoboda DM; Sallman DA
Curr Hematol Malig Rep; 2019 Dec; 14(6):550-560. PubMed ID: 31760573
[TBL] [Abstract][Full Text] [Related]
33. Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis.
Matos A; Magalhães SMM; Rauh MJ
Adv Exp Med Biol; 2021; 1326():1-10. PubMed ID: 33385175
[TBL] [Abstract][Full Text] [Related]
34. Molecular pathology of myelodysplastic syndromes: new developments and implications for diagnosis and treatment.
Zhang X; Lancet JE; Zhang L
Leuk Lymphoma; 2015; 56(11):3022-30. PubMed ID: 25927244
[TBL] [Abstract][Full Text] [Related]
35. The wider perspective: twenty years of clinical trials in myelodysplastic syndromes.
Duetz C; Cucchi DGJ; Polak TB; Janssen JJWM; Ossenkoppele GJ; Estey EH; van de Loosdrecht AA
Br J Haematol; 2022 Jan; 196(2):329-335. PubMed ID: 34632583
[TBL] [Abstract][Full Text] [Related]
36. Myelodysplastic syndrome hematopoietic stem cell.
Li J
Int J Cancer; 2013 Aug; 133(3):525-33. PubMed ID: 23047726
[TBL] [Abstract][Full Text] [Related]
37. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
38. Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?
Nazha A; Sekeres MA; Gore SD; Zeidan AM
Oncologist; 2015 Sep; 20(9):1069-76. PubMed ID: 26194858
[TBL] [Abstract][Full Text] [Related]
39. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
Stahl M; Zeidan AM
Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
[TBL] [Abstract][Full Text] [Related]
40. Myelodysplastic Syndromes: Diagnosis and Treatment.
Steensma DP
Mayo Clin Proc; 2015 Jul; 90(7):969-83. PubMed ID: 26141335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
